Product Description

Tishtha 100mg Injection contains nivolumab, a monoclonal antibody and programmed death receptor-1 inhibitor used for the treatment and management of various advanced cancers. Nivolumab works by blocking the PD-1 protein on immune cells, preventing cancer cells from using immune checkpoint pathways to evade immune detection. By inhibiting PD-1 signaling, this medicine enhances the body’s immune response to recognize and attack tumor cells, helping to control disease progression. Nivolumab-based therapies are commonly used in adults for the treatment of cancers such as non-small cell lung cancer, melanoma, renal cell carcinoma, head and neck squamous cell carcinoma, urothelial carcinoma, and other malignancies where immune checkpoint inhibition is clinically beneficial. Dosage and treatment schedules are individualized by the treating oncologist based on cancer type, disease stage, patient condition, and response to therapy. Regular monitoring and follow-up are recommended throughout the course of treatment to ensure safety and effectiveness.